|
|
|
Insider
Information: |
Emster Kurt Von |
Relationship: |
Director |
City: |
|
State: |
|
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
7 |
|
Direct
Shares |
302,614 |
|
Indirect Shares
|
18,297,697 |
|
|
Direct
Value |
$5,393,134 |
|
|
Indirect Value
|
$160,482,323 |
|
|
Total
Shares |
18,600,311 |
|
|
Total
Value |
$165,875,457 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Rigel Pharmaceuticals Inc |
RIGL |
10% Owner |
2003-06-26 |
173,611 |
2004-02-19 |
4,350,516 |
Premium* |
|
Somaxon Pharmaceuticals, Inc. |
SOMX |
Director |
2013-03-06 |
0 |
2013-03-06 |
0 |
Premium* |
|
Crispr Therapeutics Ag |
CRSP |
Director |
2018-06-05 |
90,000 |
2018-12-18 |
1,171,268 |
Premium* |
|
Cymabay Therapeutics, Inc. |
CBAY |
|
2024-03-22 |
0 |
2023-09-29 |
18,406 |
Premium* |
|
Vaxcyte, Inc. |
PCVX |
Director |
2020-06-16 |
0 |
2020-06-16 |
4,168,718 |
Premium* |
|
Vera Therapeutics, Inc. |
VERA |
Director |
2021-05-17 |
17,828 |
2021-05-18 |
2,960,231 |
Premium* |
|
Amplitude Healthcare Acquisition... |
AMHCU |
Director |
2023-04-13 |
21,175 |
2021-09-24 |
5,628,558 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
108 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 3 of 5
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
CRSP |
Crispr Therapeutics Ag |
Director |
|
2018-12-18 |
4 |
S |
$29.70 |
$2,077,101 |
I/I |
(69,925) |
1,164,268 |
0 |
- |
|
CBAY |
Cymabay Therapeutics, Inc... |
Director |
|
2017-11-10 |
4 |
AS |
$9.26 |
$463,379 |
I/I |
(50,048) |
1,166,423 |
0 |
- |
|
CRSP |
Crispr Therapeutics Ag |
Director |
|
2018-12-18 |
4/A |
S |
$29.70 |
$1,869,168 |
I/I |
(62,925) |
1,171,268 |
0 |
- |
|
CBAY |
Cymabay Therapeutics, Inc... |
Director |
|
2017-11-01 |
4 |
AS |
$9.25 |
$39,979 |
I/I |
(4,320) |
1,216,471 |
0 |
- |
|
CBAY |
Cymabay Therapeutics, Inc... |
Director |
|
2017-10-31 |
4 |
AS |
$9.27 |
$487,352 |
I/I |
(52,573) |
1,220,791 |
0 |
- |
|
CRSP |
Crispr Therapeutics Ag |
Director |
|
2018-12-17 |
4 |
S |
$33.17 |
$99,797 |
I/I |
(3,009) |
1,234,193 |
0 |
- |
|
CRSP |
Crispr Therapeutics Ag |
Director |
|
2018-05-14 |
4 |
S |
$52.20 |
$22,142,556 |
I/I |
(400,000) |
1,237,202 |
0 |
- |
|
CBAY |
Cymabay Therapeutics, Inc... |
Director |
|
2017-10-30 |
4 |
AS |
$9.26 |
$61,449 |
I/I |
(6,636) |
1,273,364 |
0 |
- |
|
CBAY |
Cymabay Therapeutics, Inc... |
Director |
|
2017-10-03 |
4 |
S |
$7.81 |
$554,041 |
I/I |
(70,940) |
1,280,000 |
0 |
- |
|
CBAY |
Cymabay Therapeutics, Inc... |
Director |
|
2017-10-02 |
4 |
S |
$7.93 |
$300,832 |
I/I |
(37,936) |
1,350,940 |
0 |
- |
|
CBAY |
Cymabay Therapeutics, Inc... |
Director |
|
2017-09-29 |
4 |
S |
$8.04 |
$970,709 |
I/I |
(120,735) |
1,388,876 |
0 |
- |
|
CBAY |
Cymabay Therapeutics, Inc... |
Director |
|
2017-09-28 |
4 |
S |
$8.15 |
$736,670 |
I/I |
(90,389) |
1,509,611 |
0 |
- |
|
CRSP |
Crispr Therapeutics Ag |
Director |
|
2018-05-11 |
4 |
S |
$51.73 |
$13,209,900 |
I/I |
(250,000) |
1,637,202 |
0 |
- |
|
CBAY |
Cymabay Therapeutics, Inc... |
Director |
|
2017-07-19 |
4 |
B |
$6.50 |
$999,999 |
I/I |
153,846 |
1,753,846 |
2.1 |
- |
|
CRSP |
Crispr Therapeutics Ag |
Director |
|
2018-01-05 |
4 |
AS |
$26.96 |
$2,489,406 |
I/I |
(92,337) |
1,821,268 |
0 |
- |
|
CRSP |
Crispr Therapeutics Ag |
Director |
|
2018-01-05 |
4 |
B |
$22.75 |
$1,499,999 |
I/I |
65,934 |
1,887,202 |
2.1 |
- |
|
CRSP |
Crispr Therapeutics Ag |
Director |
|
2018-01-02 |
4 |
AS |
$26.76 |
$1,010,123 |
I/I |
(37,754) |
1,913,605 |
0 |
- |
|
CRSP |
Crispr Therapeutics Ag |
Director |
|
2017-08-28 |
4 |
AS |
$19.79 |
$1,741,738 |
I/I |
(88,011) |
1,951,359 |
0 |
- |
|
CRSP |
Crispr Therapeutics Ag |
Director |
|
2017-08-25 |
4 |
AS |
$19.52 |
$291,102 |
I/I |
(14,913) |
2,039,370 |
0 |
- |
|
CRSP |
Crispr Therapeutics Ag |
Director |
|
2017-08-24 |
4 |
AS |
$19.23 |
$151,302 |
I/I |
(7,868) |
2,054,283 |
0 |
- |
|
CRSP |
Crispr Therapeutics Ag |
Director |
|
2017-08-23 |
4 |
AS |
$18.53 |
$130,359 |
I/I |
(7,035) |
2,062,151 |
0 |
- |
|
CRSP |
Crispr Therapeutics Ag |
Director |
|
2017-08-22 |
4 |
AS |
$18.53 |
$202,978 |
I/I |
(10,954) |
2,069,186 |
0 |
- |
|
CRSP |
Crispr Therapeutics Ag |
Director |
|
2017-08-21 |
4 |
AS |
$18.51 |
$23,138 |
I/I |
(1,250) |
2,080,140 |
0 |
- |
|
CRSP |
Crispr Therapeutics Ag |
Director |
|
2017-08-18 |
4 |
AS |
$18.53 |
$35,207 |
I/I |
(1,900) |
2,081,390 |
0 |
- |
|
CRSP |
Crispr Therapeutics Ag |
Director |
|
2017-08-17 |
4 |
AS |
$18.74 |
$254,733 |
I/I |
(13,593) |
2,083,290 |
0 |
- |
|
108 Records found
|
|
Page 3 of 5 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|